{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:02:33Z","timestamp":1740157353249,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["MISP 53535"],"award-info":[{"award-number":["MISP 53535"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clinic-based interventions are needed to promote successful direct acting antiviral (DAA) treatment for chronic hepatitis C virus (HCV) infection in patients with substance use disorders (SUDs) among rural Veterans.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We implemented a clinic-based intervention which used motivational interviewing (MI) techniques to promote medication adherence and treatment completion with 12 weeks of DAA treatment among rural Veterans with chronic HCV and SUDs. Patients received an MI session with a licensed psychologist at baseline and at each two-week follow-up visit during DAA treatment. Patients received $25 per study visit completed. Patients were to attend a laboratory visit 12 weeks after treatment completion to assess for sustained virologic response (SVR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 20 participants who enrolled, 75% (<jats:italic>n<\/jats:italic>\u2009=\u200915) completed the planned 12-week course of treatment. Average adherence by pill count was 92% (SD\u2009=\u20093%). Overall SVR was 95% (19\/20).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We demonstrated that a clinic-based intervention which incorporated frequent follow up visits and MI techniques was feasible and acceptable to a sample of predominantly rural Veterans with chronic HCV and SUDs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial registration<\/jats:title>\n                <jats:p>Registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> (NCT 02823457) on July 1, 2016. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\">https:\/\/clinicaltrials.gov<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-024-00480-8","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T05:01:46Z","timestamp":1719291706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Supporting direct acting antiviral medication adherence and treatment completion in a sample of predominantly rural veterans with hepatitis C and substance use disorders"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5509-4356","authenticated-orcid":false,"given":"Mary Jane","family":"Burton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Voluse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amee B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"480_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","volume":"108","author":"JE Zibbell","year":"2018","unstructured":"Zibbell JE, Asher AK, Patel RC, et al. Increases in Acute Hepatitis C virus infection related to a growing opioid epidemic and Associated Injection Drug Use, United States, 2004 to 2014. Am J Public Health. 2018;108:175\u201381.","journal-title":"Am J Public Health"},{"key":"480_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11904-018-0402-3","volume":"15","author":"JR Havens","year":"2018","unstructured":"Havens JR, Walsh SL, Korthuis PT, Fiellin DA. Implementing treatment of opioid-use disorder in rural settings: a focus on HIV and Hepatitis C Prevention and Treatment. Curr HIV\/AIDS Rep. 2018;15:315\u201323. https:\/\/doi.org\/10.1007\/s11904-018-0402-3","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"8","key":"480_CR3","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/liv.14043","volume":"39","author":"ME Soc\u00edas","year":"2019","unstructured":"Soc\u00edas ME, Ti L, Wood E, et al. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting. Liver Int. 2019;39(8):1400\u20137.","journal-title":"Liver Int"},{"key":"480_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa322","author":"SW Reader","year":"2020","unstructured":"Reader SW, Kim H, El-Serag HB, Thrift AP. Persistent challenges in the Hepatitis C Virus Care Continuum for patients in a Central Texas Public Health System. Open Forum Infect Dis. 2020. https:\/\/doi.org\/10.1093\/ofid\/ofaa322","journal-title":"Open Forum Infect Dis"},{"key":"480_CR5","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s10620-019-05877-z","volume":"65","author":"G Zhang","year":"2019","unstructured":"Zhang G, Patel K, Moghe A, et al. Provider perceptions of Hepatitis C treatment adherence and initiation. Dig Dis Sci. 2019;65:1324\u201333.","journal-title":"Dig Dis Sci"},{"key":"480_CR6","doi-asserted-by":"publisher","unstructured":"Patel SV, Jayaweera DT, Althoff KN et al. Real-world efficacy of direct acting antiviral therapies in patients with HIV\/HCV. Liu C-H, ed. PLOS ONE. 2020;15(2):e0228847. https:\/\/doi.org\/10.1371\/journal.pone.0228847","DOI":"10.1371\/journal.pone.0228847"},{"issue":"5","key":"480_CR7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/adm.0000000000000415","volume":"12","author":"J-B Trabut","year":"2018","unstructured":"Trabut J-B, Barrault C, Charlot H, et al. Integrated Care for the Use of Direct-acting antivirals in patients with chronic Hepatitis C and Substance Use Disorder. J Addict Med. 2018;12(5):346\u201352. https:\/\/doi.org\/10.1097\/adm.0000000000000415","journal-title":"J Addict Med"},{"issue":"9","key":"480_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.7326\/m16-0816","volume":"165","author":"GJ Dore","year":"2016","unstructured":"Dore GJ, Altice F, Litwin AH, et al. Elbasvir\u2013Grazoprevir to treat Hepatitis C virus infection in persons receiving opioid agonist therapy. Ann Intern Med. 2016;165(9):625. https:\/\/doi.org\/10.7326\/m16-0816","journal-title":"Ann Intern Med"},{"key":"480_CR9","unstructured":"Recommendations for Testing, Managing, and, Treating Hepatitis C. | HCV Guidance. www.hcvguidelines.org. http:\/\/www.hcvguidelines.org. Accessed October 10, 2020."},{"issue":"9","key":"480_CR10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.7326\/m18-1715","volume":"170","author":"MJ Akiyama","year":"2019","unstructured":"Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH. Intensive Models of Hepatitis C Care for people who inject drugs receiving opioid agonist therapy. Ann Intern Med. 2019;170(9):594. https:\/\/doi.org\/10.7326\/m18-1715","journal-title":"Ann Intern Med"},{"key":"480_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.drugpo.2017.05.032","volume":"47","author":"P Read","year":"2017","unstructured":"Read P, Lothian R, Chronister K, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy. 2017;47:209\u201315.","journal-title":"Int J Drug Policy"},{"key":"480_CR12","unstructured":"The US. National Viral Hepatitis Action Plan for 2021\u20132025.Office of HIV\/AIDS and Infectious disease policy of the U.S. Department of Health and Human Services. https:\/\/www.hhs.gov\/sites\/default\/files\/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf"},{"key":"480_CR13","unstructured":"Miller W, Rollnick S. Motivational interviewing: preparing people to change addictive behavior. Guildford; 1991."},{"issue":"4","key":"480_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.pec.2016.10.029","volume":"100","author":"PK Dillard","year":"2017","unstructured":"Dillard PK, Zuniga JA, Holstad MM. An integrative review of the efficacy of motivational interviewing in HIV management. Patient Educ Couns. 2017;100(4):636\u201346. https:\/\/doi.org\/10.1016\/j.pec.2016.10.029","journal-title":"Patient Educ Couns"},{"issue":"8","key":"480_CR15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s11606-016-3685-3","volume":"31","author":"A Palacio","year":"2016","unstructured":"Palacio A, Garay D, Langer B, Taylor J, Wood BA, Tamariz L. Motivational interviewing improves Medication Adherence: a systematic review and Meta-analysis. J Gen Intern Med. 2016;31(8):929\u201340. https:\/\/doi.org\/10.1007\/s11606-016-3685-3","journal-title":"J Gen Intern Med"},{"key":"480_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1037\/pst0000270","volume":"57","author":"A Harkness","year":"2020","unstructured":"Harkness A, Rogers BG, Puccinelli M, Ivardic I, Ironson G, Safren SA. Engaging, retaining, and providing transdiagnostic integrated cognitive\u2013behavioral therapy and motivational interviewing for underserved people with HIV. Psychother (Chic). 2020;57:15\u201322. https:\/\/doi.org\/10.1037\/pst0000270","journal-title":"Psychother (Chic)"},{"issue":"5","key":"480_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1365-2893.2011.01550","volume":"19","author":"JE Bonner","year":"2011","unstructured":"Bonner JE, Esserman D, Evon DM. Reliability and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens. J Viral Hepat. 2011;19(5):316\u201326. https:\/\/doi.org\/10.1111\/j.1365-2893.2011.01550","journal-title":"J Viral Hepat"},{"key":"480_CR18","unstructured":"US Department of Agriculture Economic Research Service. State Fact Sheets. County Level Data Sets. https:\/\/data.ers.usda.gov\/reports.aspx?ID=17827. Accessed November 11, 2020."},{"issue":"1","key":"480_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.14423\/SMJ.0000000000000750","volume":"111","author":"MJ Burton","year":"2018","unstructured":"Burton MJ, Voluse AC, Patel AB, Konkle-Parker D. Measuring adherence to Hepatitis C Direct-acting antiviral medications: using the VAS in an HCV Treatment Clinic. South Med J. 2018;111(1):45\u201350.","journal-title":"South Med J"},{"key":"480_CR20","unstructured":"Health Resources and Services Administration. Rural Health Information Hub. Am I Rural? -Tool. www.ruralhealthinfo.org\/am-i-rural. Accessed November 1, 2019."},{"issue":"5","key":"480_CR21","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/hep.26431","volume":"58","author":"NK Martin","year":"2013","unstructured":"Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58(5):1598\u2013609.","journal-title":"Hepatology"},{"issue":"4","key":"480_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/jgh.12041","volume":"28","author":"AJ Visconti","year":"2013","unstructured":"Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. J Gastroenterol Hepatol. 2013;28(4):707\u201316.","journal-title":"J Gastroenterol Hepatol"},{"key":"480_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.drugpo.2017.05.025","volume":"47","author":"K Mason","year":"2017","unstructured":"Mason K, Dodd Z, Guyton M, Tookey P, Lettner B, Matelski J, Sockalingam S, Altenberg J, Powis J. Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy. 2017;47:202\u20138.","journal-title":"Int J Drug Policy"},{"key":"480_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/cid\/ciy899","volume":"69","author":"AH Talal","year":"2019","unstructured":"Talal AH, Andrews P, Mcleod A, Chen Y, Sylvester C, Markatou M. Integrated, co-located, telemedicine-based treatment approaches for hepatitis C virus management in opioid use disorder patients on methadone. Clin Infect Dis. 2019;69:323\u201331.","journal-title":"Clin Infect Dis"},{"key":"480_CR25","doi-asserted-by":"crossref","unstructured":"Petry NM. Contingency management for substance abuse treatment: a guide to implementing this evidence-based practice. Routledge; 2012.","DOI":"10.4324\/9780203813355"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00480-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-024-00480-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00480-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T05:05:59Z","timestamp":1719291959000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-024-00480-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["480"],"URL":"https:\/\/doi.org\/10.1186\/s13722-024-00480-8","relation":{},"ISSN":["1940-0640"],"issn-type":[{"type":"electronic","value":"1940-0640"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"18 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the GVSMVAMC\u2019s Institutional Review Board. Participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}